85 related articles for article (PubMed ID: 2770701)
1. Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line.
Batist G; Torres-Garcia S; Demuys JM; Greene D; Lehnert S; Rochon M; Panasci L
Mol Pharmacol; 1989 Aug; 36(2):224-30. PubMed ID: 2770701
[TBL] [Abstract][Full Text] [Related]
2. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL).
Pu Q; Bianchi P; Bezwoda WR
Anticancer Res; 2000; 20(4):2561-8. PubMed ID: 10953327
[TBL] [Abstract][Full Text] [Related]
3. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
[TBL] [Abstract][Full Text] [Related]
4. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
5. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of a melphalan-resistant human multiple myeloma cell line.
Bellamy WT; Dalton WS; Gleason MC; Grogan TM; Trent JM
Cancer Res; 1991 Feb; 51(3):995-1002. PubMed ID: 1988143
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of melphalan resistance developed in vitro in human melanoma cells.
Parsons PG; Carter FB; Morrison L; Regius Mary Sister
Cancer Res; 1981 Apr; 41(4):1525-34. PubMed ID: 6163526
[TBL] [Abstract][Full Text] [Related]
8. DNA interstrand cross-link and free radical formation in a human multidrug-resistant cell line from mitomycin C and its analogues.
Dusre L; Rajagopalan S; Eliot HM; Covey JM; Sinha BK
Cancer Res; 1990 Feb; 50(3):648-52. PubMed ID: 2153443
[TBL] [Abstract][Full Text] [Related]
9. Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line.
Pu QQ; Bezwoda WR
Anticancer Res; 2000; 20(4):2569-78. PubMed ID: 10953328
[TBL] [Abstract][Full Text] [Related]
10. DNA damage in cyclophosphamide-resistant tumor cells: the role of glutathione.
Richardson ME; Siemann DW
Cancer Res; 1995 Apr; 55(8):1691-5. PubMed ID: 7712476
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor ethacrynic acid.
Hansson J; Berhane K; Castro VM; Jungnelius U; Mannervik B; Ringborg U
Cancer Res; 1991 Jan; 51(1):94-8. PubMed ID: 1988111
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF
Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322
[TBL] [Abstract][Full Text] [Related]
13. Expression of a rat glutathione-S-transferase complementary DNA in rat mammary carcinoma cells: impact upon alkylator-induced toxicity.
Schecter RL; Alaoui-Jamali MA; Woo A; Fahl WE; Batist G
Cancer Res; 1993 Oct; 53(20):4900-6. PubMed ID: 8402679
[TBL] [Abstract][Full Text] [Related]
14. Radiation response of drug-resistant variants of a human breast cancer cell line.
Lehnert S; Greene D; Batist G
Radiat Res; 1989 Jun; 118(3):568-80. PubMed ID: 2727277
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro mechanisms of drug resistance in a rat mammary carcinoma model.
Schecter RL; Woo A; Duong M; Batist G
Cancer Res; 1991 Mar; 51(5):1434-42. PubMed ID: 1997182
[TBL] [Abstract][Full Text] [Related]
16. Prevention of the development of melphalan resistance in vitro by selenite.
Caffrey PB; Zhu M; Frenkel GD
Biol Trace Elem Res; 1998 Dec; 65(3):187-95. PubMed ID: 9892492
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF
Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194
[TBL] [Abstract][Full Text] [Related]
18. Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation.
Belfi CA; Chatterjee S; Gosky DM; Berger SJ; Berger NA
Biochem Biophys Res Commun; 1999 Apr; 257(2):361-8. PubMed ID: 10198218
[TBL] [Abstract][Full Text] [Related]
19. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
20. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
Friedman HS; Dolan ME; Kaufmann SH; Colvin OM; Griffith OW; Moschel RC; Schold SC; Bigner DD; Ali-Osman F
Cancer Res; 1994 Jul; 54(13):3487-93. PubMed ID: 8012971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
